Superworth

Halozyme Therapeutics price to free cash flow HALO

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Nov 2, 2026
18.2×
9-year median
18.1×
Against its 9-year history
50th
percentile: 0 is its lowest day, 100 its highest
9-year range
11.3× to 129×
Peer median
25.2×

Halozyme Therapeutics' price to free cash flow is 18.2× as of Nov 2, 2026.

That is above its 9-year median of 18.1×, close to the middle of its last 9 years.

Over that time it ranged from 11.3× in Mar 2026 to 129× in Apr 2021.

The median for 10 biotech stocks of a similar size is 25.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.2×11.3×18.4×
202513.4×12.1×18.9×
202415.6×12.6×19.8×
202313.8×13.8×31.6×
202232.4×16.0×33.8×
202121.4×17.2×129×
2020n/m a value too high to mean anything
201927.1×23.4×27.1×
201822.7×17.4×26.3×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
TECHBIO-TECHNE43.3×
ALNYAlnylam Pharmaceuticals26.7×
RGENRepligen87.2×
INCYIncyte12.7×
KRYSKrystal Biotech34.0×
UTHRUnited Therapeutics23.7×
ONCBeOne Medicines30.2×
ADMAAdma Biologics21.3×
Peer median25.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.